Antibiotics or Placebo? The Effectiveness & Cost of Treating Children with Lower Respiratory Tract Infection

By Staff Writer

July 25, 2023

Antimicrobial drug resistance is a growing public health problem, particularly in relation to respiratory tract infections (RTIs) which are commonly treated in primary care. Antibiotic resistance is linked to primary care antibiotic prescribing and has significant cost implications. Despite a decrease in consultation and prescription rates for RTIs from the late 1990s to early 2000s, antibiotic use has fluctuated, rising again during the COVID-19 pandemic. Children have higher consultation rates for RTIs and are often prescribed antibiotics, even when these prescriptions are at their lowest. There is limited evidence to support the use of antibiotics for chest infections in children, and differences between adults and children mean adult-derived evidence cannot be directly applied. Both parents and clinicians have concerns about illness progression and potential adverse outcomes. The study aimed to assess the effectiveness of amoxicillin in children with uncomplicated lower respiratory tract infection.

 

A total of 432 children participated in this study- found that amoxicillin for uncomplicated lower respiratory tract infections in children is unlikely to be clinically effective or to reduce health or societal costs. The duration of symptoms was similar in the antibiotic and placebo groups, as were the rates of consultations, illness progression, and side effects. The costs per child to the NHS were slightly higher for antibiotics, but there was no difference in non-NHS costs. The study concluded that parents need better access to information and clear communication about managing their child’s illness. Clinicians also noted a reduction in parents’ expectations for antibiotics.

The study also found that the costs to the NHS per child were similar for both antibiotics and placebo (£29 vs £26), and societal costs were the same (£33). In the study they suggest that GPs should support parents to self-manage at home and provide clear communication about when and how to seek medical help. Parents whose children received antibiotics reported symptoms as moderately bad or worse for 5 days, while those given a placebo reported symptoms for 6 days. Side effects were similar in both groups. The study concluded that amoxicillin for chest infections in children is unlikely to be effective, and recommended that GPs support parents to self-manage at home while providing clear communication about when and how to seek medical help.

Reference url

Recent Posts

drug price transparency
     

Impending Net Drug Price Transparency Regulation in the U.S.

💡 Are you ready for a potential game-changer in drug pricing transparency?

CMS Administrator Mehmet Oz has hinted at a new rule aimed at enforcing stricter disclosures for drug prices, requiring healthcare companies to reveal actual transaction costs. This could reshape how price transparency is managed across the industry and challenge pharmacy benefit managers to rethink rebate practices.

Curious about how this will impact healthcare economics and what it means for drug affordability? Dive into the article for all the insights!

#SyenzaNews #healthcare #HealthEconomics

Sword Health mental health
         

How Does Mind’s AI-Driven Mental Healthcare Transform Care?

🤔 Are we ready to embrace AI in mental health care?

Sword Health has just secured €34.6 million to launch **Mind**, an innovative AI-powered mental health solution, blending licensed clinicians with continuous monitoring through wearables. This strategic expansion aims to address the pressing global mental health crisis while promoting personalized and proactive care models. 🌍🧠

Dive into how Sword Health is revolutionizing healthcare and bridging the gap between technology and clinical expertise.

#SyenzaNews #HealthTech #AIinHealthcare #DigitalTransformation

transparency in industry partnerships
   

Transparency in Industry Partnerships: Building Trust

🔍 How does transparency in industry partnerships impact patient care?

In the evolving landscape of healthcare, EFPIA’s mandatory disclosure requirements for financial interactions underscore the vital role of transparency in fostering trust and collaboration. By detailing financial transfers to healthcare professionals and organizations, the European Disclosure Gateway facilitates informed decision-making and strengthens relationships between stakeholders.

Have a look at the article to explore how these initiatives not only enhance public confidence but also drive innovation in treatments!

#SyenzaNews #HealthcareInnovation #HealthEconomics #innovation

When you partner with Syenza, it’s like a Nuclear Fusion.

Our expertise are combined with yours, and we contribute clinical expertise and advanced degrees in health policy, health economics, systems analysis, public finance, business, and project management. You’ll also feel our high-impact global and local perspectives with cultural intelligence.

SPEAK WITH US

CORRESPONDENCE ADDRESS

1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA

© 2025 Syenza™. All rights reserved.